ClinicalTrials.gg
Enrolling by invitationNCT06891079Updated Mar 24, 2025

Videodensitometric Angiographic Assessment of AR in the Cath-lab for Intraprocedural Guidance of TAVI in CHINA

An interventional study of Videodensitometric guided and Stand of care guided in Aortic Stenosis, sponsored by Xijing Hospital. Enrolling by invitation at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Xijing Hospital · Not applicable, Interventional, and Diagnostic

How we know · 2 judgments

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Mar 2024, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Planned enrollment
7th of 47
320 · median 120
Started
2024
with 10 others
No phase
37 of 69
20 open now
Primary completion
2026-12
later than 28 of 50 live
Registered
51st of 69
by date
Lead sponsor
4 of 69
Xijing Hospital

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 7th largest by planned enrollment of the 47 interventional ones that give a count, is one of 11 that started in 2024, is one of 37 with no phase, reaches primary completion later than 28 of the 50 other live ones, and was the 51st registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

This clinical trial, a prospective, randomized, multicenter study, assigns patients to either videodensitometry-guided TAVI or conventional TTE/TEE-guided TAVI (stand of care), with the primary endpoint being regurgitation fraction measured by cardiac magnetic resonance (CMR) at discharge. Current AR assessment methods, like subjective visual grading or intraprocedural TTE, face limitations in objectivity and practicality, whereas videodensitometry offers real-time, quantitative feedback to guide corrective actions (e.g., post-dilation) during TAVI. If proven non-inferior, this approach could streamline workflows by reducing reliance on general anesthesia and complex imaging, potentially lowering complications and expanding accessibility, particularly in centers lacking advanced echocardiography resources.

Read the detailed description

As the transcatheter aortic valve implantation (TAVI) procedure matures, complications such as paravalvular regurgitation (PVR), stroke, conduction disturbances, vascular complications, and annular rupture have been targeted for further improving the long-term outcome of TAVI. Paravalvular regurgitation (PVR) is associated with mortality following TAVI, even in those with mild PVR. Accurate procedural assessment of AR-critical for successful TAVI. Aortic root angiography, typically using Seller's visual grading, is the first screening tool used in most laboratories for the detection of post-implantation AR and guidance of timely corrective measures (e.g. post-dilation, valve-in-valve and, most recently, retrieval and reposition of the valve). However, the Sellers classification of aortic regurgitation (AR) is subjective. Some centers use transthoracic echo to confirm residual AR. However, performing transthoracic echo in the Cath-lab in a prone position is challenging. Previous studies have demonstrated that TAVI performed exclusively under angiographic guidance with backup TTE is feasible and associated with reasonably good outcomes, similar to those of angiography and TEE-guided procedures. Quantitative aortographic assessment of AR is important for procedural TAVI guidance to facilitate timely decision-making to avert AR using balloon post-dilatation, retrieval-reposition, or valve-in-valve implantation.

CAAS A-Valve (quantitative assessment of regurgitation with videodensitometry in the left ventricle outflow tract) is a new tool to quantify AR developed by Pie Medical. This tool is an angiographic methodology that proved to be accurate, feasible, reproducible, and predictive of outcomes after TAVI. After extensive validation of this new technology in two different cohorts (from the Brazilian TAVI registry and Bad-Segeberg, Germany), hereby we propose to apply this currently off-line technology to guide decision making in the Cath-lab during TAVI.

The present trial is a prospective, randomized, controlled, open-label, multi-center, non-inferiority trial. The primary objective of this trial is to determine whether TAVI procedure guided by videodensitometric assessment of aortography is non-inferior to TAVI implantation guided by Standard of care (usual practice) in terms of postprocedural quantitative aortic regurgitation. The primary endpoint of the study will be the Cardiac magnetic resonance-derived regurgitation fraction at discharge. This project is the first study to investigate the clinical utility of using video-densitometry in a randomized, controlled clinical trial to guide TAVI procedure. In centers with no current CAAS-A Valve software, Pie Medical will provide a research lease during the study period.

03

Conditions studied

  • Aortic Stenosis

Keywords

  • Aortic stenosis
  • transcatheter aortic valve implantation
  • videodensitometry
  • Paravalvular regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has aortic stenosis with indication of TAVI implantation as determined by Heart Team.
  2. Patient is at least 18 years of age.
  3. Signed . The patient understands and accepts clinical follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Subject is not willing to provide an form, or whose legal heirs object to their participation in the study.
  2. If the patient is not suitable for participating in the study, based on the evaluation by the operators.
  3. Cardiogenic shock.
  4. Significant comorbidities precluding clinical follow-up (as judged by investigators).
  5. History of TAVI or SAVR.
  6. Renal insufficiency (/MDRD \<45 ml/min), which precludes in operator's opinion contrast injection during repeat aortography.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Experimental arm

    TAVI procedure guided by post-implantation aortographic quantitative videodensitometric assessment.

    Diagnostic Test: Videodensitometric guided

  • Active comparator
    Control arm

    TAVI procedure guided by post-implantation standard of care according to local practice.

    Diagnostic Test: Stand of care guided

Interventions

  • Diagnostic testVideodensitometric guided

    In the experimental arm, a TAVI device is implanted according to the local practice. Immediately after implantation, aortography is performed to quantitatively assess the aortic regurgitation (qAR). The aortography is analyzed using CAAS A-Valve (Pie-Medical, Maastricht, The Netherlands). •If qAR is \>17%, we recommend that corrective post-TAVI manoeuvres (post-dilatation, valve-in-valve, etc.) will be performed and angiography is repeated for the assessment of aortic regurgitation. If the qAR ≤17%, whether corrective post-TAVI manoeuvres (post-dilatation, valve-in-valve, etc.) will be performed is left to the discretion of the operators. Inform operators of the results of qAR and the threshold criteria. Continuous qAR was stratified into categorical variables according to the following pre-determined threshold criteria: (1) none or trace (qAR \<6%); (2) mild (6% to ≤17%); and (3) moderate or severe (\>17%). At discharge, all the patients will undergo Cardiac magnetic resonance, the Car

  • Diagnostic testStand of care guided

    In the control arm, a TAVI device is implanted according to local practice. Immediately after implantation, TEE/TTE or aortography is performed as a part of usual practice. * The requirement of post-dilatation or any additional procedure is left to the discretion of the operator. * The operator judges the sufficient procedural outcome to end the procedure according to local practice. At discharge, all the patients will undergo Cardiac magnetic resonance, the Cardiac magnetic resonance-derived regurgitation fraction (CMR-RF) will be analyzed as the primary endpoint.

06

What researchers measure

Primary outcomes

  1. CMR-derived regurgitation fraction

    The Cardiac magnetic resonance-derived regurgitation fraction at discharge.

    Time frame: at discharge 1 day, an average of 7days

Secondary outcomes

  1. Medical cost

    Direct medical cost at discharge

    Time frame: at discharge 1 day, an average of 7days

  2. Radiation dose

    Amount of radiation dose

    Time frame: during the procedure

  3. Time in the Cathlab

    Time in the Cathlab

    Time frame: during the procedure

  4. Time for the TAVI procedure

    Time for the TAVI procedure

    Time frame: during the procedure

  5. All-cause mortality and its sub-categories

    All-cause mortality and its sub-categories defined by VARC 3

    Time frame: at discharge 1 day, an average of 7days; 30-day; 1 year

  6. All strokes

    All strokes

    Time frame: at discharge 1 day, an average of 7days;30-day; 1 year

  7. Any hospitalization and its sub-categories

    Any hospitalization and its sub-categories defined by VARC 3

    Time frame: 30-day, 1 year

  8. Acute Kidney Injury (AKI)

    Acute Kidney Injury (AKI)(VARC 3 criteria: use the widely recognized kidney disease: Improving Global Outcomes (KDIGO) definition of AKI)

    Time frame: at discharge 1 day, an average of 7days; 30-day

  9. Type 3 (life-threatening) or Type 4 (leading to death) bleeding

    Type 3 (life-threatening) or Type 4 (leading to death) bleeding (VARC-3 criteria)

    Time frame: at discharge 1 day, an average of 7days; 30-day; 1 year

  10. Mild or more prosthetic valve regurgitation

    Mild or more prosthetic valve regurgitation \[TTE assessment

    Time frame: 30-day, 1 year

  11. New permanent pacemaker implantation

    New permanent pacemaker implantation \[VARC-3 criteria\]

    Time frame: at discharge 1 day, an average of 7days; 30-day, 1 year

  12. Conduction disturbances and arrhythmias

    Conduction disturbances and arrhythmias according to VARC-3

    Time frame: at discharge 1 day, an average of 7days; 30-day; 1 year

  13. Technical success:

    * Freedom from mortality * Successful access, delivery of the device, and retrieval of the delivery system * Correct positioning of a single prosthetic heart valve into the proper anatomical location * Freedom from surgery or intervention related to the devicea or to a major vascular or access-related, or cardiac structural complication

    Time frame: patient exit from procedure room,whichever came first,assessed up to 30 minutes

  14. Device success

    * Technical success * Freedom from mortality * Freedom from surgery or intervention related to the devicea or to a major vascular or access-related or cardiac structural complication * Intended performance of the valvec (mean gradient \<20 mmHg, peak velocity \<3 m/s, Doppler velocity index \>_0.25, and less than moderate aortic regurgitation)

    Time frame: 30-day

  15. Myocardial infarction

    Myocardial infarction (VARC-3 criteria)

    Time frame: at discharge 1 day, an average of 7days; 30-day; 1 year

  16. Vascular and access-related complications

    Vascular and access-related complications (VARC-3 criteria)

    Time frame: at discharge 1 day, an average of 7days; 30-day; 1 year

  17. Cardiac structural complications

    Cardiac structural complications (VARC-3 criteria)

    Time frame: at discharge 1 day, an average of 7days; 30-day; 1 year

  18. Any adverse events

    Any adverse events

    Time frame: within 7 days

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 33 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2025
First posted
Mar 24, 2025
StartActual
Mar 28, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06891079
Lead sponsor
Xijing Hospital
Responsible party
Ling Tao, MD, PhD (Professor, Xijing Hospital) — Principal investigator
First posted
Mar 24, 2025
Start date
Mar 28, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 24, 2025

Study contacts

Ling Tao, PhD
study chair · Xijing Hospital, Xi'an, Shannxi, China
Junbo Ge, PhD
principal investigator · Zhongshan hospital, Fudan University, Shanghai, China
Patrick Washington Serruys, PhD
study chair · National University of Ireland Galway, Galway, Ireland
Yoshinobu Onuma, Ph D
study chair · National University of Ireland Galway, Galway, Ireland
Daxin Zhou, PhD
study chair · Zhongshan hospital, Fudan University, Shanghai, China
Rutao Wang, PhD
study chair · Xijing Hospital, Xi'an, Shannxi, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion